Frederik Cleeren

ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 9

Top Venues

European journal of nuclear medicine and molecular imaging

Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Nature protocols

EJNMMI research

KU Leuven

KU Leuven (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

KU Leuven Sep 21 2016

Belgium

Postdoctoral Researcher laboratory for radiopharmaceutical sciences :: Pharmaceutical and pharmalogical sciences

Education History

KU Leuven Sep 21 2012 - Sep 21 2016

Belgium

PHD :: Pharmaceutical and Pharmacological sciences

KU Leuven Sep 24 2010 - Jun 30 2012

Belgium

MSC :: farmaceutische en farmacologische wetenschappen

Publications

Janke Kleynhans, Thomas Ebenhan, Frederik Cleeren, Machaba Michael Sathekge
Can current preclinical strategies for radiopharmaceutical development meet the needs of targeted alpha therapy? European journal of nuclear medicine and molecular imaging 51 (7) (2024)
Janke Kleynhans, Thomas Ebenhan, Frederik Cleeren, Machaba Michael Sathekge
Can current preclinical strategies for radiopharmaceutical development meet the needs of targeted alpha therapy? European journal of nuclear medicine and molecular imaging 51 (7) (2024)
Janke Kleynhans, Thomas Ebenhan, Frederik Cleeren, Machaba Michael Sathekge
Can current preclinical strategies for radiopharmaceutical development meet the needs of targeted alpha therapy? European journal of nuclear medicine and molecular imaging (2024)
Janke Kleynhans, Thomas Ebenhan, Frederik Cleeren, Machaba Michael Sathekge
Can current preclinical strategies for radiopharmaceutical development meet the needs of targeted alpha therapy? European journal of nuclear medicine and molecular imaging 51 (7) (2024)
Joana F Santos, Maria T Braz, Paula Raposinho, Frederik Cleeren, Irwin Cassells, Simon Leekens, Christopher J Cawthorne, Filipa Mendes, Célia Fernandes, António Paulo
Synthesis and Preclinical Evaluation of PSMA-Targeted 111 In-Radioconjugates Containing a Mitochondria-Tropic Triphenylphosphonium Carrier. Molecular pharmaceutics (2023)
Guy Bormans, Frederik Cleeren
Radiopharmaceuticals for Cancer Imaging and Therapy. Pharmaceutics 15 (9) (2023)
Elin Pauwels, Frederik Cleeren, Térence Tshibangu, Michel Koole, Kim Serdons, Lennert Boeckxstaens, Jeroen Dekervel, Timon Vandamme, Willem Lybaert, Bliede Van den Broeck, Annouschka Laenen, Paul M Clement, Karen Geboes, Eric Van Cutsem, Sigrid Stroobants, Chris Verslype, Guy Bormans, Christophe M Deroose
18 F-AlF-NOTA-octreotide outperforms 68 Ga-DOTA-TATE/-NOC PET in neuroendocrine tumor patients: results from a prospective, multicenter study. Journal of nuclear medicine : official publication, Society of Nuclear Medicine (2022)
Sarah Belderbos, Manuel A Gonzalez Gómez, Frederik Cleeren, Jens Wouters, Yolanda Piñeiro-Redondo, Christophe M Deroose, An Coosemans, Willy Gsell, Guy Bormans, Jose Rivas, Uwe Himmelreich
Simultaneous in vivo PET/MRI using fluorine-18 labeled Fe3O4@Al(OH)3 nanoparticles: comparison of nanoparticle and nanoparticle-labeled stem cell distribution. EJNMMI research 10 (1) (2020)
Frederik Cleeren, Joan Lecina, Jessica Bridoux, Nick Devoogdt, Térence Tshibangu, Catarina Xavier, Guy Bormans
Direct fluorine-18 labeling of heat-sensitive biomolecules for positron emission tomography imaging using the Al18F-RESCA method. Nature protocols 13 (10) (2019)

Frederik Cleeren.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Frederik Cleeren